News

LSL Pharma Group Secures $6.44 Million as the First Closing of Concurrent Non-Brokered Private Placements

$2.7M cash investments secured including $0.4M from Insiders $3.75M of Debt converted BOUCHERVILLE, Quebec, March 19, 2024 (GLOBE NEWSWIRE) --…

2 years ago

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan,…

2 years ago

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

2 years ago

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and…

2 years ago

SPEVIGO® approved for expanded indications in China and the US

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as…

2 years ago

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK,…

2 years ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage…

2 years ago

Unauthorized Access to Employee Mobile Devices Leads to More Than Half of Organizations Experiencing a Data Breach, New Report Finds

Research conducted by Imprivata and Ponemon Institute finds 28% of IT and IT security practitioners say their organizations can secure…

2 years ago

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No…

2 years ago

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company…

2 years ago